Producer
ICU Medical
Third largest US IV fluid producer, formed through 2017 acquisition of Pfizer's Hospira Infusion Systems. Entered joint venture with Japan's Otsuka Pharmaceutical Factory in 2025 (renamed Otsuka ICU Medical LLC), combining Austin TX plant with Otsuka's 16 IV solution sites across Asia.
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input ICU Medical supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something ICU Medical makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
IV Solutions (Hospira Infusion Systems heritage)
45%Infusion Systems (CLAVE Needleless Connectors)
35%Oncology & Critical Care Products
20%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Note2025
ICU Medical completed a joint venture in May 2025 with Japan's Otsuka Pharmaceutical Factory (OPF), which acquired a 60% stake in ICU Medical's IV solutions business — creating Otsuka ICU Medical LLC. The combined entity, with OPF's 16 IV solution sites across Asia, becomes one of the world's largest IV fluid networks producing an estimated 1.4 billion units annually, substantially diversifying US supply chain geography.
ICU Medical ↗Did you know2023
ICU Medical operates across two distinct hospital care supply chains from a single company: (1) IV fluid manufacturing (saline, dextrose, electrolytes) — consumed in bulk by hospitals for hydration, drug dilution, and maintenance in general patients; (2) IV delivery system hardware (CLAVE needleless connectors, ChemoClave for cytotoxic drugs, infusion pumps) — precision medical devices required for safe IV administration. The hardware-software bundling model is notable: hospitals using ICU Medical IV bags are encouraged to also use ICU Medical needleless connectors, creating a lock-in similar to printer/ink cartridge models. The same company manufacturing commodity fluid bags also manufactures the precision connectors through which those fluids are delivered — and has a distinct oncology business (ChemoClave CSTD systems) for chemotherapy drug administration safety that requires completely separate manufacturing standards, regulatory clearances, and pharmacist workflows. A IV solution commodity manufacturer is simultaneously a specialty oncology drug delivery safety device supplier.
ICU Medical, Inc. ↗Origin2023
ICU Medical's current position as a major US IV fluid manufacturer is the result of a chain of corporate transactions spanning 20 years: Abbott Laboratories operated the IV fluid business (including the Austin TX plant) as part of its hospital products division; Abbott spun out Hospira (a standalone hospital products company) in 2004 as part of strategic restructuring; Pfizer acquired Hospira in 2015 for USD 17 billion to enter the generic injectable drug business; Pfizer then decided Hospira Infusion Systems (the IV bag manufacturing) was non-strategic and sold it to ICU Medical in 2017 for approximately USD 600 million. An IV plant that Abbott built, Hospira operated, Pfizer acquired as an afterthought, and then sold at a fraction of the acquisition price is now #3 in US IV fluids. ICU Medical's 2025 joint venture with Otsuka Pharmaceutical Factory (Japan) — forming Otsuka ICU Medical LLC — further restructures the ownership, connecting the former Pfizer-acquired Abbott IV plant to Japanese pharmaceutical manufacturing operations.
ICU Medical, Inc. ↗